As part of our cancer research programinto lysyl oxidase (LOX) inhibitors, we required a scalable routeto chiral 3,6-diazabicyclo[3.2.2]nonanes (bridged homopiperazines) 1 (Figure 1).2 The configuration of the dimethyl-substitutedbridge of this stereoisomer imparted superior stability to our inhibitorsagainst in vivo metabolism compared with a range of bridged homopiperazineisomers. Here, LOX is linked to cancer.